Trade

with

Cyclacel Pharmaceuticals Inc
(NASDAQ: CYCC)
AdChoices
3.24
-0.01
-0.31%
After Hours :
3.24
0.00
0.00%

Open

3.23

Previous Close

3.25

Volume (Avg)

60.07k (86.03k)

Day's Range

3.21-3.29

52Wk Range

2.68-5.25

Market Cap.

73.70M

Dividend Rate ( Yield )

-

Beta

1.15

Shares Outstanding

22.68M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.08M

    • Net Income

    • -10.15M

    • Market Cap.

    • 73.70M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,405.74

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.15

    • Forward P/E

    • -

    • Price/Sales

    • 47.17

    • Price/Book Value

    • 2.48

    • Price/Cash flow

    • -3.83

      • EBITDA

      • -11.81M

      • Return on Capital %

      • -50.90

      • Return on Equity %

      • -63.18

      • Return on Assets %

      • -50.90

      • Book Value/Share

      • 1.30

      • Shares Outstanding

      • 22.68M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 34.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 4.33

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -1,533.31

            • 39.38

            • Net Profit Margin

            • -1,405.74

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 65.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -5,987.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -5,853.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 4.79

              • 2.92

              • Quick Ratio

              • 4.57

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.27

              • 2.21

              • Book Value/Share

              • 1.30

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.27

                • 196.08

                • P/E Ratio 5-Year High

                • -29.46

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.60

                • 124.82

                • Price/Sales Ratio

                • 46.08

                • 9.12

                • Price/Book Value

                • 2.43

                • 8.26

                • Price/Cash Flow Ratio

                • -3.83

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -63.18

                        (-111.30)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -50.90

                        (-72.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -63.18

                        (-110.30)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.04

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -17.97M
                      Operating Margin
                      -1,658.12
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -3.83
                      Ownership

                      Institutional Ownership

                      10.52%

                      Top 10 Institutions

                      9.73%

                      Mutual Fund Ownership

                      5.88%

                      Float

                      96.28%

                      5% / Insider Ownership

                      4.50%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Allianz Biotechnologie

                      •  

                        506,865

                      • 0.00

                      • 2.23

                      • Vanguard Extended Market Index Fund

                      •  

                        318,555

                      • 1.37

                      • 1.40

                      • Vanguard Total Stock Mkt Idx

                      •  

                        311,182

                      • 0.00

                      • 1.37

                      • iShares Micro-Cap

                      •  

                        66,697

                      • 1.28

                      • 0.31

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        58,323

                      • 0.00

                      • 0.26

                      • Vanguard Balanced Index Fund

                      •  

                        20,223

                      • 0.00

                      • 0.09

                      • EB DL Non-SL Market Completion Fund

                      •  

                        12,241

                      • 592.76

                      • 0.05

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        11,529

                      • 0.00

                      • 0.05

                      • DFA U.S. Micro Cap Portfolio

                      •  

                        4,300

                      • 0.00

                      • 0.02

                      • AXA/Lord Abbett Micro Cap Portfolio

                      •  

                        4,055

                      • 0.00

                      • 0.02

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Group, Inc.

                      •  

                        637,190

                      • +5.99%

                      • 2.81

                      • Allianz Global Investors U.S. LLC

                      •  

                        506,865

                      • 0.00%

                      • 2.23

                      • Allianz Global Investors

                      •  

                        506,865

                      • -9.36%

                      • 2.24

                      • Goldman, Sachs & Co.

                      •  

                        136,856

                      • +3.95%

                      • 0.60

                      • Invesco Private Capital, Inc.

                      •  

                        116,316

                      • 0.00%

                      • 0.51

                      • Geode Capital Management, LLC

                      •  

                        71,273

                      • -0.03%

                      • 0.31

                      • BlackRock Fund Advisors

                      •  

                        70,631

                      • +2.94%

                      • 0.31

                      • Rotella Capital Management Inc

                      •  

                        37,472

                      • +90.80%

                      • 0.17

                      • Northern Trust Investments, N.A.

                      •  

                        33,627

                      • +1.93%

                      • 0.15

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a development-stage biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted d...morerugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Cyclacel's clinical development priorities are focused on sapacitabine for the treatment of Acute myeloid leukemia, Myelodysplastic syndromes, and Non-small cell lung cancer. Apart from sapacitabine, the Company has generated anticancer drugs that act on cell cycle such as seliciclib and CYCO65. Current...morely the Company is evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. It is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.lessless

                      Key People

                      Spiro Rombotis

                      CEO/President/Director

                      Dr. David C. U'Prichard,PhD

                      Chairman of the Board/Director

                      Dr. Christopher S. Henney, PhD

                      Director/Vice Chairman of the Board

                      Paul Mcbarron

                      CFO/Chief Accounting Officer/COO/Director/Executive VP, Divisional/Secretary

                      Judy Chiao,M.D.

                      Vice President, Divisional

                      • Cyclacel Pharmaceuticals Inc

                      • 200 Connell Drive

                      • Berkeley Heights, NJ 07922

                      • USA.Map

                      • Phone: +1 908 517-7330

                      • Fax: +1 866 271-3466

                      • cyclacel.com

                      Incorporated

                      1996

                      Employees

                      18

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: